NCT00393588 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG
Multiple sclerosis. N Engl J Med. 2000 Sep 28;343(13):938-52. Review.
Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L, Milanov I
The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006 Jul;13(7):700-22. Review.
Sospedra M, Martin R
Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683-747. Review.

The Use of Magnetic Resonance Imaging to Investigate Cortical Damage in Patients With Multiple Sclerosis and Correlation With Cognitive Dysfunction

Clinical trial NCT00393588 - References